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Table S1.  Combinations of Gαi and Gαq dependent GPCR ligands yield synergistic Ca2+ 
responses.   
 C5a UDP UTP   
UDP Y nd N  Apparent Gα Linkage 
UTP Y N nd  i 
LPA N Y Y  q 
S1P Y Y nd  i/q 
Spir N Y Y   
 
NIH-3T3 cells stably expressing C5aR or Ro2 were stimulated with combinations of C5a (10 nM), UTP 
(100 µM), UDP (100 µM), LPA (50 nM), S1P (50 nM), and Spiradoline (Spir, 100 nM).  Ligands 
dependent on PTx-sensitive G-proteins are labeled in blue. Ligands showing partial sensitivity to PTx are 
labeled in green. Ligands insensitive to PTx and presumed to be dependent on Gαq are labeled in red.    
“Y” indicates the presence of synergy from dual-ligand stimulations, inferred from replicate assays, and 
“N” indicates the absence of synergy.  Combinations for which synergy was not determined are marked 
‘nd’. 
 
Figure S1. Expression of mPLCβ3 in PLCβ2/3-/- BMDM restores synergistic Ca2+ responses to levels 
observed in WT BMDM.  Single cell Ca2+ assays were performed on WT or PLCβ2/3-/- BMDM 
transduced with retrovirus encoding YFP-FLAG or YFP-mPLCβ3.  Cells were stimulated with C5a (0.75 
nM), UDP (500 nM), or C5a+UDP, and the Ca2+ responses were measured by integration over 2.25 min.    
The predicted additive (Pred. Additive) response was calculated as the sum of the UDP and C5a 
responses.  Synergy ratios calculated as the ratio of the observed UDP+C5a response to the predicted 
additive response are displayed in Fig. 2E. Responses by transduced cells were measured in multiple 
assays of each of 3 independent batches of infected BMDM.  Values shown are mean +/- SEM from n=5-
6 samples per condition.  *p<0.05. 
 
Figure S2. Ligand dose-responses.  Intracellular Ca2+ levels were calculated for Fura-2 loaded NIH-
3T3-C5aR cells.  Cells were stimulated with varied concentrations of (A) UTP, UDP or C5a and (B) 
LPA, S1P or PAF.  Values are mean +/- SEM from n=4-8 samples per point. 
 
Figure S3.  Robust synergy is observed for ligands that stimulate little to no Ca2+ response 
individually.  Intracellular Ca2+ levels were calculated for Fura-2-loaded NIH-3T3-C5aR cells.  (A) Cells 
were stimulated with 1 or 10 nM C5a alone or in combination with 100 µM UDP.  (B) Cells were 
stimulated with 25 or 100 µM UDP alone or in combination with 10 nM C5a.  Peak offsets for C5a alone 
were 0-15 nM (median = 8 nM) while UDP yielded no measurable responses.  Values shown are mean +/-
SEM of n=4 samples per condition per assay from a representative assay of n=4 with similar results. 
 
Figure S4.  C5a stimulated Ca2+ responses and synergistic responses with UTP are PTx-sensitive.  
NIH-3T3 cells stably expressing C5aR were treated for 18 h with buffer or 50 ng/ml PTx and Ca2+ assays 
were performed to assess single-ligand and synergy responses.  (A) Responses of cells to 10 nM C5a with 
or without pretreatment with PTx.  (B) Responses of cells pretreated with buffer to 10 nM C5a, 100 µM 
S2 
UTP, or C5a+UTP.  The predicted additive response is shown, and the calculated synergy ratio for this 
assay = 2.0.  (C) Responses of cells pretreated with PTx to 10 nM C5a, 100 µM UTP, or C5a+UTP.  The 
predicted additive response is shown, and the calculated synergy ratio for this assay = 1.3.  Values are 
mean from n=4 samples from a representative assays of two with similar results. 
 
Figure S5. Alternate Gαi-linked GPCRs provide synergy with UTP and UDP.   (A) Responses to 
LPA and S1P are PTx-sensitive.  NIH-3T3 cells pretreated with PTx (50 ng/ml for 18 h) were stimulated 
with 100 µM UTP, 2.5 µM LPA, or 1 µM S1P.  (B) UDP synergizes with LPA or S1P.  Cells were 
stimulated with 100 µM UDP, 50 nM LPA, and 50 nM S1P alone or in combination.  Peak offset synergy 
ratios for dual ligand stimulations were 4.9 and 3.7 for UDP+LPA and UDP+S1P respectively.  Results 
are from representative assays of n=3-4 each. (C) NIH-3T3 cells stably expressing the Ro2 RASSL form 
of the human kappa opioid receptor respond to spiradoline (Spir) in a PTx-sensitive manner.  Cells treated 
with or without PTx (50 ng/ml for 18 h) were stimulated with 100 nM Spir. (D) Spiradoline synergizes 
with UTP.  Cells were treated with 100 µM and 500 nM Spir alone or in combination.    Quantitation of 
responses was by peak-offset for each condition. The synergy ratio for the dual-ligand stimulation was 3.  
Results are from a representative assay of n=4 with similar results. 
 
Figure S6. Ca2+ responses to spiradoline alone and its synergistic response with UTP are PTx-
sensitive.  NIH-3T3 cells stably expressing Ro2 receptor were treated for 18 h with buffer (A) or 50 
ng/ml PTx (B), and Ca2+ assays were performed to assess synergy responses.  (C) Peak-offsets of 
responses were measured and synergy ratios of 2.6 and 1.2 were calculated for buffer and PTx treatments, 
respectively. 
 
Figure S7.  Levels of PLCβ isoform knockdown and YFP-PLCβ expression in NIH-3T3 
cells.  (A)  siRNA-mediated KD of PLCβ isoforms was performed in NIH-3T3-C5aR cells using PLCβ 
isoform specific siRNA versus LacZ control siRNA.  After 72 h, RNA samples were taken in parallel 
with analyses of Ca2+ responses.   PLCβ isoform mRNA levels were measured by qRT-PCR and 
expressed as percent change vs LacZ control siRNA samples.  (B) NIH-3T3 cells were stably transfected 
with YFP or YFP-tagged murine PLCβ isoforms and analyzed by FACS to measure YFP-fusion protein 
expression.  (C) NIH-3T3 cells were stably transfected with YFP or YFP-tagged bovine PLCβ4 (wild-
type or C-terminal mutant (∆CT)) and analyzed by FACS to measure YFP-fusion protein expression. (D) 
PLCβ4 inhibition of synergy is dependent on its Gαq binding region. NIH-3T3 cells were stably 
transfected with YFP-bPLCβ4, YFP-bPLCβ4∆CT (C-terminal mutant), or YFP vector control and 
assayed for Ca2+ response synergy to UTP + C5a.  Synergy ratios were calculated for peak offset values.  
Values are mean+/-SEM from 2-3 assays using 2 independently derived cell lines per target, *p<0.05 
versus YFP. 
 
Figure S8.  Levels of PLCβ3 expression and knockdown in NIH-3T3 cells.  siRNA-mediated 
knockdown of mPLCβ3 was performed in NIH-3T3-C5aR cells stably expressing YFP or YFP-tagged 
PLCβ constructs.  After 72 h, total protein and RNA samples were taken in parallel with analyses of Ca2+ 
responses.  (A)  Western blotting for mPLCβ3 in YFP or YPF-hPLCβ3-expressing cells treated with 
mPLCβ3 isoform-specific siRNA versus LacZ control siRNA.  Arrows indicate endogenous mPLCβ3 
and introduced YFP-hPLCβ3. (B)  mPLCβ3 mRNA was measured by qRT-PCR.  Levels are expressed as 
percent change vs LacZ control siRNA samples. 
 
Figure S9.  Transfection of PLCβ isoforms and mutants into NIH-3T3 cells.  NIH-3T3 cells were 
stably transfected with YFP or YFP-tagged PLCβ constructs including:  intact hPLCβ3; C-terminal 
S3 
mutant, hPLCβ3∆CT; Y-box mutant, hPLCβ3∆YB, C-terminal mutant hPLCβ3∆YB∆CT, intact 
mPLCβ2, and a C-terminal deletion mutant of mPLCβ2 (PLCβ2−CT).  (A) Cells were analyzed by FACS 
to measure YFP-fusion protein expression.  (B)  Cells were then subjected to RNAi using murine-specific 
anti-PLCβ3 or LacZ control siRNA. After 72 h, RNA samples were taken in parallel with analyses of 
Ca2+ responses.   mPLCβ3 mRNA was measured by qRT-PCR.   Levels are expressed as percent change 
vs LacZ siRNA control samples.  (C) C5a+UTP synergy ratios were calculated for each cell line and 
treatment (see Figs. 7,8) and the changes in synergy ratio (differences in synergy ratio between LacZ 
control and mPLCβ3-specific siRNA) for each cell line were calculated to determine the delta with 
knockdown of mPLCβ3.  A delta of zero (0) reflects no change in synergy with mPLCβ3 KD, and thus 
the ability of the introduced construct to substitute for endogenous mPLCβ3.  Values are mean+/-SEM 
from n=6-15 assays using 2-7 independently derived cell lines per target.  (D) PLCβ2 can substitute for 
PLCβ3 to mediate Ca2+ synergy in NIH-3T3 cells.  NIH-3T3 cells were stably transfected with YFP or 
YFP-tagged PLCβ constructs including:  intact mPLCβ2 or a C-terminal deletion mutant of mPLCβ2 
(PLCβ2−CT).  Cells were then subjected to RNAi using murine-specific anti-PLCβ3 or LacZ control 
siRNA.  Synergy ratios were calculated for each cell line and treatment and the changes in synergy ratio  
for each cell line were calculated to determine the delta with knockdown of mPLCβ3. Although intact 
mPLCβ2 maintained synergy (y=0 shows no change in synergy with KD of mPLCβ3), the C-terminal 
mutant did not, *p<0.05. Values are mean+/-SEM from n=3-7 assays using 2-3 independently derived cell 
lines per target. 
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